About this Medicine article
The Biochemical Aftermath of Anti-amyloid Immunotherapy by Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Eliezer Masliah; James AR Nicoll; Marwan N Sabbagh; Thomas G Beach; Eduardo M Castaño; Alex E Roher is a Medicine article available to read on EtoBox.
## Abstract ## Background Active and passive immunotherapy in both amyloid-beta precursor protein (APP) transgenic mice and Alzheimer's Disease (AD) patients have resulted in remarkable reductions in amyloid plaque accumulation, although the degree of amyloid regression has been highly variable. Nine individuals with a clinical diagnosis of AD dementia were actively immunized with the Aβ peptide 1-42 (AN-1792) and subjected to detailed postmortem biochemical analyses. These patients were compared to 6 non-immunized AD cases and 5 non-demented control (NDC) cases. ## Results All patients were assessed for the presence of AD pathology including amyloid plaques, neurofibrillary tangles and vascular amyloidosis. This effort revealed that two immunotherapy recipients had dementia as a consequence of diseases other than AD. Direct neuropathological examination consistently demonstrated small to extensive areas in which amyloid plaques apparently were disrupted. Characterization of Aβ species remnants by ELISA suggested that total Aβ levels may have been reduced, although because the amounts of Aβ peptides among treated individuals were extremely variable, those data must be regarded as t
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Eliezer Masliah; James AR Nicoll; Marwan N Sabbagh; Thomas G Beach; Eduardo M Castaño; Alex E Roher
- Publisher
- BioMed Central; Springer (Biomed Central Ltd.); London: BioMed Central, 2006-; Springer Science and Business Media LLC (ISSN 1750-1326)
- Published
- 2010
- Language
- EN
- Field
- Medicine (Health Sciences)